Oculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short Interest

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 21,700 shares, a growth of 29.9% from the May 15th total of 16,700 shares. Based on an average daily volume of 37,400 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on OCS shares. Chardan Capital raised their price target on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. HC Wainwright upped their price objective on Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, April 17th. Finally, Robert W. Baird lifted their price target on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a report on Thursday, March 13th.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bellevue Group AG acquired a new stake in shares of Oculis in the fourth quarter valued at $170,000. XTX Topco Ltd bought a new position in shares of Oculis during the 4th quarter valued at about $225,000. Kestra Private Wealth Services LLC acquired a new position in shares of Oculis in the 1st quarter worth approximately $234,000. Geode Capital Management LLC raised its holdings in shares of Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Oculis during the fourth quarter valued at approximately $389,000. 22.30% of the stock is owned by institutional investors.

Oculis Stock Performance

Shares of OCS traded down $0.05 during trading hours on Tuesday, reaching $19.20. 229 shares of the company's stock traded hands, compared to its average volume of 45,015. Oculis has a twelve month low of $10.79 and a twelve month high of $23.08. The business's fifty day simple moving average is $18.35 and its two-hundred day simple moving average is $18.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The firm has a market capitalization of $838.09 million, a price-to-earnings ratio of -9.95 and a beta of 0.35.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.26). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The company had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.22 million. Analysts predict that Oculis will post -2.09 earnings per share for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.